缬沙坦和卡托普利对兔血管平滑肌细胞组织因子和组织因子途径抑制物表达及活性的影响  

Effects of valsartan and captopril on expressions and activities of tissue factor and tissue factor pathway inhibitor

作　　者：黎娜[1] 朱文玲[2] 陈莲凤[2] 柯元南[1] 

机构地区：[1]卫生部中日友好医院心内科,北京1000029 [2]北京协和医院心内科

出　　处：《中华心血管病杂志》2006年第10期922-928,共7页Chinese Journal of Cardiology

摘　　要：目的观察氧化修饰低密度脂蛋白(ox-LDL)、血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂对血管平滑肌细胞组织因子(TF)和组织因子途径抑制物(TFPI)表达和活性的影响。方法采用组织贴块法培养兔主动脉平滑肌细胞,进行形态学和α-肌动蛋白(actin)免疫组化鉴定。在细胞水平,采用免疫组化、免疫荧光法检测 ox-LDL 和缬沙坦对 TF、TFPI 蛋白表达的影响,激光共聚焦法检测 ox-LDL 和缬沙坦对 TF 蛋白表达的影响,ELISA 法检测 ox-LDL、缬沙坦和卡托普利对 TF、TFPI抗原表达的影响,发色底物法检测 ox-LDL、缬沙坦和卡托普利对 TF 活性的影响,RT-PCR 检测 ox-LDL和缬沙坦对 TF mRNA 表达的影响。结果 ox-LDL 可增加兔血管平滑肌细胞 TF 抗原活性和 mRNA的表达,在 mRNA 水平调节 TF 的表达。ox-LDL 可降低兔血管平滑肌细胞 TFPI 抗原的表达。不同浓度的缬沙坦和卡托普利可明显减少 ox-LDL 刺激的平滑肌细胞 TF 抗原表达及活性,缬沙坦对 TF 表达的影响呈浓度依赖性,同时缬沙坦还可明显减少 ox-LDL 刺激的 TF mRNA 表达,证明缬沙坦在 mRNA水平上调节 TF 的表达。不同浓度的缬沙坦和卡托普利可增加 ox-LDL 刺激的血管平滑肌细胞 TFPI抗原的表达,缬沙坦对 TFPI 表达的影响呈浓度依赖性,该结果由 ELISA 法得出。结论本实验在细胞水平观察到 ox-LDL 对血管平滑肌细胞 TF 表达和活性有促进作用,血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂对其有抑制作用,但这两种药对 TFPI 的表达有促进作用。从一个新的角度说明这两种药对动脉粥样硬化斑块特别是斑块促凝性的影响,它们可能是通过部分调节 TF 和 TFPI 的表达水平而发挥作用的。Objective To investigate the effects of ox-LDL, ACEI and ARB on expressions and activities of TF and TFPI in VSMC. Methods （ 1 ） Rabbit VSMC was cultured by explant-attached method in vitro. （2） The effects of ox-LDL and valsartan on TF and TFPI expressions were analyzed by immunohistochemistry and immunofluorscence. Laser scanning confocal microscopy were applied to analyze the effects of ox-LDL and valsartan on TF expression. The effects of ox-LDL, valsartan and captopril on TF and TFPI antigen expressions were analyzed by ELISA. Chromogenic substrate method was used to determine the effects of ox-LDL, valsartan and captopril on TF activity. The effects of ox-LDL and valsartan on TF mRNA expression were analyzed by RT-PCR. Results （ 1 ） oxoLDL could upregulate TF antigen, activity and TF expression at mRNA level and downregulate TFPI antigen. （2） Valsartan and captopril could reduce TF antigen and activity in VSMC treated by ox-LDL, and valsartan reduce it in a dose-dependent manner. Valsartan could also attenuate TF expression at mRNA level in VSMC treated by ox-LDL. （3） Using ELISA, valsartan and captopril could also enhance TFPI antigen in VSMC treated by ox-LDL Conclusion Our study showed upregulated TF and downregulated TFPI expression and activity by ox-LDL and these effects could be reversed by ACEI and ARB indicating a new insight on the antiatherosclerotic effects of ACEI and ARB.

关 键 词：动脉硬化 凝血致活酶 血管紧张素转换酶抑制药 血管紧张素受体拮抗剂 

分 类 号：R543[医药卫生—心血管疾病]